Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index, and 1 are not checked yet.

Triglycerides on the rise: should we swap seats on the seesaw?

Open access
Libby, Peter · 2015 · European Heart Journal

Abstract

For decades, cardiovascular risk attributed to lipids beyond low-density lipoprotein (LDL) has focused appropriately on high-density lipoprotein (HDL). Indubitable observational data show a consistent inverse relationship between baseline HDL-C concentrations and cardiovascular risk. Yet, fidelity as a prospective risk marker does not guaranty that an analyte either lies in a causal pathway for disease, or that its therapeutic manipulation will yield clinical benefits. Indeed, multiple strategies to raise HDL levels therapeutically have thus far failed to forestall events in clinical trials [e.g. currently available fibrates, niacin, and the investigated cholesteryl ester transfer protein (CETP) inhibitors]. We await eagerly with an open mind, however, results from the ongoing outcome trials with two additional CETP inhibitors. We also recognize that steady-state concentrations of HDL-C in plasma likely do not reflect the flux of HDL particles, their potential for mediating reverse cholesterol transport, and other putative functions of HDL subclasses. For example, a large body of in vitro and experimental animal studies indicates that HDL particles may have many beneficial actions beyond reverse cholesterol transport. These putative properties of HDL particles include anti-oxidant and anti-inflammatory effects, attributes not assessed by the simple laboratory measurement of HDL-C. These functional facets of HDL may provide novel targets for therapeutic manipulation in a more subtle fashion in the future. Yet, concordant with the data from clinical intervention trials showing lack of benefit (or even harm) with current approaches to pharmacological boosting of HDL-C, recent genetic studies have also cast doubt on HDL-C as a causal risk factor.1 While HDL-C has stood in the spotlight, centre stage, triglycerides have tarried in the wings as a causal cardiovascular risk factor. Adjustment for HDL-C and for other potential confounders tends to attenuate or nullify the association between triglyceride concentration and prospective cardiovascular risk.2,3 HDL-C and triglyceride concentration in plasma tend to vary inversely, such that high levels of triglycerides associate with low levels of HDL, until recently the presumed causal partner in the pair (Figure 1). Curiously, we generally measure fasting triglycerides, although many spend most of their time in post-prandial in the state, bathing our arteries with triglyceride-rich lipoproteins.4 Yet, current data show that either fasting or fed triglyceride concentrations associate with cardiovascular events.5,6 The high-density lipoprotein/triglyceride seesaw. High-density lipoprotein and triglycerides tend to vary inversely. Traditional thought has focused on the benefits of raising high-density lipoprotein and high-density lipoprotein as a protective factor for atherosclerosis. Triglycerides have received less attention as a causal risk factor as adjustment for high-density lipoprotein attenuates its association with risk. The new clinical and genetic data described in this commentary indicate that triglycerides and specifically the apolipoprotein constituent of many triglyceride-rich lipoproteins, apolipoprotein C3, may actually lie in the causal pathway for atherosclerosis. Thus, contrary to common belief, the current data suggest that we should focus more on triglyceride-rich lipoproteins as a target for cardiovascular risk reduction. Fasting or fed, perhaps adjusting triglycerides for HDL-C, instead of the other way around, has misled us. Have we have collectively chosen a seat on the wrong side of the HDL/triglyceride seesaw? (Figure 1). Recent genetic studies have occasioned a re-examination of triglycerides as a causal cardiovascular risk factor. Contemporary genetic analyses indicate that higher concentrations of triglyceride and remnant lipoproteins contribute directly to the pathogenesis of ischaemic heart disease.7,8 The cholesterol content of remnant particles rather than triglycerides themselves likely comprise the causal moiety contained in this lipoprotein class.9 The actual gene or genes responsible for this association have remained conjectural. One protein associated with triglyceride-rich lipoproteins, apolipoprotein C3 (APOC3), associates with cardiovascular risk. The study of the Amish population in Pennsylvania suggested that carriers of an inactive APOC3 gene have lower triglycerides and lower coronary artery calcium scores than unaffected individuals.10 Two independent large studies recently published in New England Journal of Medicine provide strong evidence for the causal role of APOC3 and triglycerides in atherosclerotic vascular disease.11,12 Exxon sequencing of large cohorts in the USA tracked four loss-of-function variants in APOC3. The individuals with such variants had lower triglyceride concentrations, and correspondingly lower risk of coronary heart disease in validation studies. A parallel study performed in Danish populations t

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu500

Cites

17 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 18 references

Cited by

See all 92

Metadata

Authors
Libby, P.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Libby, Peter
Venue
European Heart Journal
Published
2014-12-29
Volume
36
Issue
13
Pages
774-776
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2107665972
Cited by
85
References
18
Citations by year
2026: 2 · 2025: 1 · 2024: 7 · 2023: 10 · 2022: 10 · 2021: 14 · 2020: 5 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 4
FWCI
5.95
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL080472)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
triglycerides, HDL cholesterol, cardiovascular risk, triglyceride-rich lipoproteins, postprandial lipemia, reverse cholesterol transport, HDL subfractions, CETP inhibitors, HDL-raising therapy, triglyceride-lowering therapy, dyslipidemia, cardiovascular outcome trials, nicotinic acid, fibrates
MeSH terms
Cardiovascular Diseases, Fasting, Humans, Cholesterol, HDL, Mutation, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triglycerides on the rise: should we swap seats on the seesaw? https://app.cochat.ai/papers/10.1093/eurheartj/ehu500
The paper
Libby, P. (2015). Triglycerides on the rise: should we swap seats on the seesaw? European Heart Journal. https://doi.org/10.1093/eurheartj/ehu500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.